Hyperhomocysteinemia: An emerging and important risk factor for thromboembolic and cardiovascular disease

American Journal of Clinical Pathology

Volumn 106, Issue 6, 1996, Pages 709-722

  Guba, Susan C ^a,b   Fink, Louis M ^a,b   Fonseca, Vivian ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Cardiovascular disease; Folate; Homocysteine; Homocystinuria; Methionine; Thromboembolism; Vitamins

Indexed keywords

HOMOCYSTEINE;

AMINO ACID METABOLISM; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; HUMAN; HYPERHOMOCYSTEINEMIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOEMBOLISM; VASCULAR ENDOTHELIUM;

EID: 0030460152     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/106.6.709     Document Type: Review

References (94)

1. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease, Am J Hum Genet 1996;58:35-41.
2. Motulsky AG. Nutritional Ecogenetics: Homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet 1996;58:17-20.
3. Mudd SH, Levy HL. Plasma homocyst(e)ine or homocysteine? N Engl J Med 1995;333:325.
4. 6, pyridoxal phosphate, and folate. Am J Cardiol 1995;75:1107-111.
5. Selhub J, Jacques PR, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotidartery stenosis. N Engl J Med 1995;332:286-291.
6. Malinow MR. Plasma homocyst(e)ine and arterial occlusive diseases: A mini-review. Clin Chem 1995;41:173-176.
7. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-1057.
8. Stabler SP, Marcell PD, Podell ER, et al. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 1988;81:466-474.
9. Clarke R. Daly L, Robinson K, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324:1149-1155.
10. den Heijer MD, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-762.
11. Mandel H, Brenner B, Berant M, et al. Coexistence of hereditary homocystinuria and factor V Leiden: Effect on thrombosis. N Engl J Med 1996;334:763-768.
12. Boers GHJ, Smals AG, Trijbels FJ, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-715.
13. De Stefano V, Finazzi G. Mannucci PM. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management. Blood 1996;87:3531-3544.
14. Mudd SH, Levy HL, Skovby F: Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, ed 7. New York: McGraw-Hill, 1995, pp 1279-1327.
15. Ueland PM, Refsum H, Stabler SP, et al. Total homocysteine in plasma or serum: Methods in clinical applications. Clin Chem 1993;39:1764-1779.
16. Anderson A, Isaksson A, Hultberg B. Homocysteine export from erythrocytes and its implication for plasma sampling. Clin Chem 1992;38:1311-1315.
17. Rasmussen K, Moller J, Lyngbak M, Pedersen A-MH, Dybkjer L. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin Chem 1996;42:630-636.
18. Department of Health and Human Services. Food standards: Amendment of standards of identity for enriched grain products to require addition of folic acid. Federal Register 1996;61: 8781-8807.
19. Ubbink JB, Becker PJ, Vermaak WJH, Delport R. Results of B-vitamin suplementation study used in a prediction model to define a reference range for plasma homocysteine. Clin Chem 1995;41:1033-1037.
20. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987;422:43-52.
21. Ubbink JB, Vermaak WJH, Bissbort S. Rapid high performance liquid Chromatographic assay for total homocysteine levels in human serum. Eur J Clin Chem Clin Bio Chem 1991;29:549-554.
22. Fiskerstrand T, Refsum H, Kvalheim G, Eulan PM. Homocysteine and other thiols in plasma and urine: Automated determination in sample stability. Clin Chem 1993;39:263-271.
23. Evrovski J, Kalaghan M, Cole DEC. Determination of homocysteine by HPLC with pulsed integrated amperometry. Clin Chem 1995;41:757-758.
24. Andersen A, Isaksson A, Brattström, Hultberg B. Homocysteine and other thiols determined in plasma by HPLC and thiol-specific postcolumn derivatization. Clin Chem 1993;39:1590-1597.
25. Shipchandler MT, Moore EG. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott Imx Analyser. Clin Chem 1995;41:991-994.
26. Brenton DP, Cusworth DC, Gaull GE. Homocystinuria: Metabolic studies on three patients. J Pediatr 1965;67:58-68.
27. Mansoor MA, Svardal AM, Schneede J, Eulan PM. Dynamic relation between reduced, oxidized, and protein-bound homocystine in other thiol components in plasma during methionine loading in healthy men. Clin Chem 1992;38:1316-1321.
28. Fenton WA, Rosenberg LE. Inherited disorders of cobalamin transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, ed 7. New York: McGraw-Hill, 1995, pp 3129-3149.
29. Kraus JP, Le K, Swaroop M, et al. Human cystathionine b-synthase cDNA: sequence, alternate splicing and expression in cultured cells. Hum Mol Genet 1993;2:1633-1638.
30. Kluijtmans LAJ, Blom HJ, Boers GHJ, et al. Two novel missense mutations in the cystathionine b-synthase gene in homocystinuric patients. Hum Genet 1995;96:249-250.
31. Tsai MY, Hansom NQ, Schwichtenberg K, Garg U. Amplification refractory mutation system to identify mutations in cystathionine b-synthase deficiency. Clin Chem 1995;41:1775-1777.
32. Clarke R, Daly L, Rosinson K, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324:1149-1155.
33. Brattström L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990;81:51-60.
34. Goyette P, Sumner JS, Milos R, et al. Human methylenetetrahydrofolate reductase isolation of cDNA, mappng and mutation identification. Nature Genet 1994;7:195-200.
35. Errata. Re: Goyette P, Sumner JS, Milos R, et al. Human methylenetetrahydrofolate reductase isolation of cDNA, mappng and mutation identification. Nature Genet 1994;7:551.
36. Visy JM, Le Coz P, Chadefauz B, et al. Homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency revealed by stroke in adult siblings. Neurology 1991;41:1313-1315.
37. Rang SS, Wong PWK, Susmano A, et al. Thermolabile Methylenetetrahydrofolte Reductase: An inherited risk factor for coronary artery disease. Am J Hum Genet 1991;48:536-545.
38. Kang SS, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993;88:1463-1469.
39. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995;10:111-113.
40. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-881.
41. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relationship of serum homocystine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994;106:9-19.
42. Ubbink JB, Vermaak WJ, Delport R, et al. Effective homocysteine metabolism may protect South African blacks against coronary heart disease. Am J Clin Nutr 1995;62:802-808.
43. Malinow MR, Kang SS, Taylor LM, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180-1188.
44. Munshi MN, Stone A, Fink L, Fonseca V. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism 1996;45:133-135.
45. Fermo I, D'Angelo V, Paroni R, et al. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995;123:747-753.
46. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocysteinemia with juvenile venous thrombosis. Arterioscler Thromb 1994;14:1080-1083.
47. Lingren A, Brattstrom L, Norrving B, et al. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995;26:795-800.
48. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile: The Hordaland homocysteine study. JAMA 1995;274:1526-1533.
49. Malinow MR, Levenson J, Giral P. et al. Role of blood pressure, uric acid, and hemorrheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis 1995;114:175-183.
50. Glueck CJ, Shaw P, Lang JE, et al. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995;75:132-136.
51. Bostom A, Brosnan JT, Hall B, Nadeau MR, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995;116:59-62.
52. Bostom AG, Shemin D, LaPane K, et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996;49:147-152.
53. Massy ZA, Chadefaxu-Vekemans B, Chevalier A, et al. Hyperhomocysteinemia: A significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994;9:1103-1108.
54. Arnadottir M, Hultberg B, Vladov V, et al. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996;61:509-512.
55. Eritsland J. Arnesen H, Seljeflot I, et al. Influence of serum Lipoprotein(a) and homocysteine levels on graft patency after coronary artery bypass grafting. Am J Cardiol 1994;74:1099-1102.
56. Berger PB, Jones JD, Olson LJ, et al. Increase in total plasma homocysteine concentration after cardiac transplantation. Mayo Clin Proc 1995;70:125-131.
57. von Eckardstein A, Malinow MR, Upson B, et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocysteinemia as a cardiovascular risk factor in men. Arterioscler Thromb Vasc Biol 1994;14:460-464.
58. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698.
59. Joosten E, Pelemans W, Devos P, et al. Cobalamin absorption and serum homocysteine and methylmalonic acid in elderly subjects with low serum colbalamin. Eur J Hematol 1993;51:25-30.
60. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976;58:731-741.
61. Di Minno G, Davi G, Margaglione M, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria: Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993;92:1400-1406.
62. RatnoffOD. Activation of Hageman factor by L-homocystine. Science 1968;162:1007-1009.
63. Rodgers GM. Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990;75:895-901.
64. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991;88:1906-1914.
65. Harpel PC. Zhang X, Borth W. Homocysteine and hemostasis: Pathogenetic mechanisms predisposing to thrombosis. J Nutr 1996;126:12855-12895.
66. Munnich A, Saudubray JM, Dautzenberg MD, et al. Diet responsive proconvertin (factor VII) deficiency in homocystinuria. J Pediatr 1983;102:730-734.
67. Giannini MJ, Coleman M, Innerfield I. Antithrombin activity in homocystinuria. Lancet 1975;1:1094.
68. Lieberman ER, Gomperts ED, Shaw KNF, Landing BH, Donnell GN. Homocystinuria: Clinical and pathologic review, with emphasis on thrombotic features, including pulmonary artery thrombosis. Perspect Pediatr Pathol 1993;125-147.
69. Schienle HW, Seitz R, Rohner I, et al. Coagulation factors and markers of activation of coagulation in homocystinuria (HOCY): A study in two siblings. Blood Coagul Fibrinolysis 1994;5:873-878.
70. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb vASC bIOL 1993;13:1327-1333.
71. DeGroot PG, Willems C, Boers GJ, et al. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest 1983;13:405-410.
72. Blom HJ, Leinveld Ha, Boers GH, et al. Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinaemia. Eur J Clin Invest 1995;25:149-154.
73. Stamler JS, Loscalzo J. Endothelium-derived relaxing factor modulates the atherothrombogenic effects of homocysteine. J Cardiovasc Pharmacol 1992;20:S202-S204.
74. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-318.
75. Celermajer DS, Sorensen K, Ryalls M, et al. Impaired enddothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Col Cardiol 1993;22:854-858.
76. Van den Berg M, Boers GH, Franken DG, et al. Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995;25: 176-181.
77. Bienvenu T, Ankri A, Chadefaux B, Montalescot G, Kamoun P. Elevated total plasma homocysteine, a risk factor for thrombosis: Relation to coagulation and fibrinolytic parameters. Thromb Res 1993;70:123-129.
78. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993;92:1381-1386.
79. Quere I, Habib A, Tobelem G. Maclouf J. Inhibition of cyclooxygenase activity in human endothelial cells by homocysteine. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:397-399.
80. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc-Natl Acad Sci USA 1994;91:6369-6373.
81. Rolland PH, Friggi A, Barlatier A, et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995;91:1161-1174.
82. Franken DG, Boers GH, Blom HJ, Trijbels FJ, Kloppenborg PW. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb Vasc Biol 1994;14:465-470.
83. Palareti G, Salardi S, Piazzi S, et al. Blood coagulation changes in homocystinuria: Effects of pyridoxine and other specific therapy. J Pediatr 1986; 109:1001-1006.
84. Morrow G III. Barness LA. Combined vitamin responsiveness in homocystinuria. J Pediatr 1972;81:946-954.
85. Lipson MH, Kraus J, Rosenberg LE. Affinity of cystathionine b synthase for pyridoxal 5′-phosphate in cultured cells: A mechanism for pyridoxine-responsive homocystinuria. J Clin Invest 1980;66:188-193.
86. Brattström LE, Hultberg BL, Hardebo JE. Folic acid responsive postmenopausal homocysteinemia. Metabolism 1985;34: 1073-1077.
87. Landgren F, Israelsson B, Lindgren A, et al. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med 1995;237:381-388.
88. Smolin LA, Benevenga NJ, Berlow S. The use of betaine for the treatment of homocystinuria. J Pediatr 1981;99:467-472.
89. Wilcken DE, Wilcken B, Dudman NP, Tyrrell PA. Homocystinuria: The effect of betaine in the treatment of patients not responsive to pyridoxine. N Engl J Med 1983;309:448-453.
90. Bostom AG, Shemin D, Nadeau, et al. Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation [Letter]. Atherosclerosis 1995;113: 129-132.
91. Olszewski AJ, McCully KS. Fish oil decreases serum homocysteine in hyperlipemic men. Coron Artery Dis 1993;4:53-60.
92. Anker G, Lonning PE, Ueland PM, Refsum H, Lien EA. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen. Cancer 1995;60:365-368.
93. Refsum H, Ueland PM. Clinical significance of pharmacological modulation of homocysteine metabolism. Trends Pharmacol Sci 1990;11:411-416.
94. van der Mooren MJ, Wouters MG, Blom HJ, et al. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994;24:733-736.